The following is a summary of the Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Ionis Pharmaceuticals reported first-quarter revenues of $119 million, half of which came from commercial products such as SPINRAZA and WAINUA.

• Non-GAAP operating expenses increased year-over-year due to investment in growth opportunities.

• Cash and investments totaled $2.2 billion at end of quarter.

• Revenue growth potential is supported by a rich pipeline, substantial royalty revenue, and milestone potentials from partnered programs.

Business Progress:

• Key advancements include U.S. launch of WAINUA and the preparation for the launch of olezarsen and donidalorsen.

• Submission of NDA for olezarsen expected to receive U.S. approval by year-end.

• ION224 made progress by meeting primary and key secondary endpoints in Phase 2 trial for NASH and will be licensed out.

• Multiple products in pipeline including zilganersen, pelacarsen, bepirovirsen, and ALS drug ION541 aiming to provide strong future revenue growth.

• Ongoing trials including the CARDIO-TTRansform trial for TTR cardiomyopathy expected to complete by mid-2026 and Phase II trial for DGAT2 inhibitor in patients with NASH demonstrating reductions in liver fat, inflammation, and fibrosis.

• Continuation of Phase 2 study for sapablursen for treatment of polycythemia vera with preliminary data indicating efficacy.

More details: Ionis Pharmaceuticals IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.